SLC3A2 Knockout A-549 Cell Line
Cat.No.:
EDC08247
Species:
Human
Cell Name:
A-549
Gene:
SLC3A2
Gene ID:
6520
Size:
1×10⁶cells
SLC3A2 Knockout Cell Line (A549) is an exclusive upgraded CRISPR/Cas9 system-mediated gene knockout cell, with the advantages of Optimized Strategy Design, Efficient Cell Transfection, High-Performance Cas9 Protein and Hassle-Free Cell Selection.
| Cat.No. | EDC08247 |
|---|---|
| Product Name | SLC3A2 Knockout A549 Cell Line |
| Cell Line | A-549 |
| Cellosaurus ID | CVCL_0023 |
| Cell Line Synonyms | A 549, A549, NCI-A549, A549/ATCC, A549 ATCC, A549ATCC, hA549 |
| Gene | SLC3A2 |
| NCBI Gene ID | |
| Gene Synonyms | 4F2|4F2HC|4T2HC|CD98|CD98HC|MDU1|NACAE |
| Summary |
This gene is a member of the solute carrier family and encodes a cell surface, transmembrane protein. The protein exists as the heavy chain of a heterodimer, covalently bound through di-sulfide bonds to one of several possible light chains. The encoded transporter plays a role in regulation of intracellular calcium levels and transports L-type amino acids. Alternatively spliced transcript variants, encoding different isoforms, have been characterized. [provided by RefSeq, Nov 2010]
|
| Associated Diseases | Non-Small Cell Lung Carcinoma |
| Morphology | Adherent |
| Passage Ratio | 1/5-1/4 ,2days |
| Complete Culture Medium | F-12K + 10% FBS |
| Freezing Medium | 95% Complete culture medium + 5% DMSO |
| QC | Indels validated by Sanger sequencing; sterility confirmed via microbial testing. |
* For research use only. Not intended for use in humans or animals, including clinical, therapeutic, or diagnostic purposes.
| Loci | STR Info (Sample Cell) Sample Cell Line: A-549 | STR Info (Cell bank) Cell Line: A-549 | ||
| Allele1 | Allele2 | Allele1 | Allele2 | |
| Amelogenin | X | Y | X | Y |
| CSF1PO | 10 | 12 | 10 | 12 |
| D2S1338 | 24 | 24 | ||
| D3S1358 | 16 | 16 | ||
| D5S818 | 11 | 11 | ||
| D7S820 | 8 | 11 | 8 | 11 |
| D8S1179 | 13 | 14 | 13 | 14 |
| D13S317 | 11 | 11 | ||
| D16S539 | 11 | 12 | 11 | 12 |
| D18S51 | 14 | 17 | 14 | 17 |
| D19S433 | 13 | 13 | ||
| D21S11 | 29 | 29 | ||
| FGA | 23 | 23 | ||
| Penta D | 9 | 9 | ||
| Penta E | 7 | 11 | 7 | 11 |
| TH01 | 8 | 9.3 | 8 | 9.3 |
| TPOX | 8 | 11 | 8 | 11 |
| vWA | 14 | 14 | ||
| D6S1043 | 11 | 13 | ||
| D12S391 | 18 | 18 | ||
| D2S441 | 10 | 13 | 10 | 13 |
* STR authentication data of this cell line matches with that of cell lines sourced from ATCC, DSMZ, JCRB, and RIKEN databases.
Conclusion: The STR identification of this cell is correct.
Conclusion: The STR identification of this cell is correct.
FAQ
Which is better for studying SLC3A2 function, SLC3A2 Knockout A-549 Cell Line or SLC3A2 overexpression A-549 Cell Line?
The choice depends on whether you are studying SLC3A2 (4F2hc/CD98)'s role as the heavy chain partner for heterodimeric amino acid transporters or its functions in integrin signaling and cancer biology. The Knockout line is the standard tool for asking whether 4F2hc is required for surface expression and function of LAT1, LAT2, xCT, and other heterodimeric SLC7 family transporters — 4F2hc partnership is essential for these transporters' membrane localization and stability. Overexpression is useful for studying CD98's reported role in integrin clustering and signaling, distinct from its transporter chaperone function.
For amino acid transporter research, the EDITGENE 4F2hc Knockout in A-549 is highly informative because 4F2hc loss simultaneously disrupts multiple heterodimeric transporters (LAT1, LAT2, xCT, asc-1, y+LAT1, y+LAT2). A-549 expresses LAT1 and xCT, making this lung cancer background relevant for studying amino acid transporter pharmacology in NSCLC. Rescue with wild-type or signaling-deficient 4F2hc separates transporter chaperone from integrin-related functions.
What are the application scenarios for this model?
Primary applications:
• Multi-transporter dependency: loss of 4F2hc simultaneously disrupts LAT1, LAT2, xCT, and other SLC7 family transporters — critical genetic tool for combined analysis.
• LAT1 amino acid uptake: ³H-leucine uptake assays to confirm functional consequences of 4F2hc loss on LAT1-mediated transport.
• xCT cystine/glutamate exchange: cystine uptake and ferroptosis sensitivity assays given 4F2hc partnership with xCT.
• Integrin signaling studies: CD98 cytoplasmic tail interactions with β1 integrin and downstream signaling effects, separable from transporter chaperone functions.
EDITGENE recommends this model for researchers investigating heterodimeric amino acid transporter biology, ferroptosis, and CD98-integrin signaling in lung cancer contexts.
Is this SLC3A2 Knockout A-549 Cell Line compatible with overexpression rescue experiments?
Yes. 4F2hc rescue experiments require attention to its dual chaperone/signaling functions:
• Construct design: use a codon-modified SLC3A2 sequence with a small C-terminal cytoplasmic tag (FLAG, HA). 4F2hc is a type II membrane protein — preserve the disulfide-linked extracellular domain that mediates SLC7 partner interactions.
• Cytoplasmic tail-deleted rescue: cytoplasmic tail deletion separates SLC7 transporter chaperone function from integrin signaling roles — critical for distinguishing these dual functions.
• Disulfide bond mutant rescue: cysteine mutations affecting heterodimer formation with SLC7 partners enable assessment of transporter-related functions specifically.
• Functional readout: rescue should restore surface expression of LAT1, LAT2, xCT, and other SLC7 partners (assessed by cell surface biotinylation) and downstream amino acid uptake activities.
A-549 transduces efficiently with lentivirus and supports stable rescue line generation.
* Research Use Disclaimer: Content is generated from publicly available research data, bioinformatic resources, and computational analyses for research reference only.
download